Shanghai Runshi Pharmaceutical Technology Co., Ltd
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Explore linked clinical trials.6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas | High Grade Meningioma | Not yet recruiting | Phase 3 | 2026-05-29 | NCT07613450 | |
| A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Not yet recruiting | Phase 2 | 2024-12-18 | NCT06739213 | |
| Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. | Unresectable Locally Advanced or Metastatic Solid Tumors | Not yet recruiting | Phase 1 / Phase 2 | 2024-11-12 | NCT06682611 | |
| A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma | Advanced Oesophageal Squamous Cell Carcinoma | Not yet recruiting | Phase 3 | 2024-10-24 | NCT06656091 | |
| A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past; Expressing Human Epidermal Growth Factor Receptor-2 (HER-2); Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 1 / Phase 2 | 2024-09-05 | NCT06577376 | |
| A Study of Simmitinib Plus SG001 in Advanced Solid Tumors | Advanced Solid Tumor | Not yet recruiting | Phase 1 / Phase 2 | 2023-11-15 | NCT06132217 |